Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

J Diabetes Res. 2017;2017:9328347. doi: 10.1155/2017/9328347. Epub 2017 Mar 12.

Abstract

Mesenchymal stem cells (MSCs), an ideal cell source for regenerative therapy with no ethical issues, play an important role in diabetic foot ulcer (DFU). Growing evidence has demonstrated that MSCs transplantation can accelerate wound closure, ameliorate clinical parameters, and avoid amputation. In this review, we clarify the mechanism of preclinical studies, as well as safety and efficacy of clinical trials in the treatment of DFU. Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.

Publication types

  • Review

MeSH terms

  • Adipose Tissue / metabolism
  • Bone Marrow Cells / cytology
  • Cell Movement
  • Clinical Trials as Topic
  • Diabetes Complications / therapy
  • Diabetic Foot / therapy*
  • Foot Ulcer / therapy*
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology*
  • Phenotype
  • Transplantation, Autologous
  • Transplantation, Homologous
  • Wound Healing*